[關(guān)鍵詞]
[摘要]
目的 培美曲塞聯(lián)合順鉑治療非小細(xì)胞肺癌(NSCLC)患者的效果及對(duì)患者血清microRNA-19、白細(xì)胞介素-27(IL-27)、轉(zhuǎn)化生長(zhǎng)因子-β1(TGF-β1)、基質(zhì)金屬蛋白酶2(MMP-2)水平的影響。方法 選取河南科技大學(xué)第一附屬醫(yī)院收治的97例NSCLC患者,收治時(shí)間2014年1月-2016年2月,隨機(jī)分為兩組,其中觀察組49例,采用培美曲塞+順鉑治療,對(duì)照組48例,采用吉西他濱+順鉑治療。連續(xù)化療2個(gè)周期后進(jìn)行臨床療效評(píng)價(jià),并比較兩組血清microRNA-19、IL-27、TGF-β1、MMP2水平。結(jié)果 治療前,觀察組和對(duì)照組的血清microRNA-19、IL-27、TGF-β1、MMP2水平比較,差異無統(tǒng)計(jì)學(xué)意義;治療后,觀察組患者的血清microRNA-19、TGF-β1、MMP2水平顯著的低于對(duì)照組(P<0.05),血清IL-27水平顯著的高于對(duì)照組(P<0.05)。觀察組患者的緩解率42.86%顯著的高于對(duì)照組的22.92%,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);觀察組的總有效率87.76%高于對(duì)照組的79.17%,但差異無統(tǒng)計(jì)學(xué)意義。治療過程中,觀察組和對(duì)照組的各種不良反應(yīng)發(fā)生率比較,差異均無統(tǒng)計(jì)學(xué)意義。結(jié)論 培美曲塞聯(lián)合順鉑治療NSCLC患者能顯著的改善血清microRNA-19、TGF-β1、MMP2水平,從而達(dá)到提高治療效果的目的。
[Key word]
[Abstract]
Objective Pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC) patients and the effects of microRNA-19 on serum interleukin -27 (IL-27), transforming growth factor beta 1 (TGF-beta 1), matrix metalloproteinase 2 (MMP-2) level of influence. Methods A total of 97 cases of NSCLC patients in our hospital from January 2014, to February 2016, of which 49 cases were treated with pemetrexed + cisplatin treatment (observation group), 48 patients were treated with gemcitabine plus cisplatin treatment (control group), continuous chemotherapy clinical curative effect was evaluated after 2 cycles. Results Before treatment, observation group and control group, serum microRNA-19 IL-27, TGF beta 1 and MMP2 levels, the difference was not statistically significant. After treatment, the observation group of patients with serum microRNA-19, TGF beta 1 and MMP2 were significantly lower than that of control group (P<0.05), the serum level of IL-27 was significantly higher than that of control group (P<0.05). The remission rate of observation group 42.86% was significantly higher than that of control group 22.92% (P<0.05). Efficiency of observation group was 87.76%,which higher than that of the control group 79.17%, but the difference was not statistically significant. In the course of treatment, observation group and control group all kinds of adverse reaction rate comparison, difference there was no statistical significance. Conclusion Pemetrexed combined with cisplatin in the treatment of patients with NSCLC can significantly improve serum microRNA-19, TGF-beta 1, MMP2 levels, so as to achieve the purpose of improving the therapeutic effect.
[中圖分類號(hào)]
[基金項(xiàng)目]